Skip to main content
Best News Website or Mobile Service
WAN-IFRA Digital Media Awards Worldwide
Best News Website or Mobile Service
Digital Media Awards Worldwide
Hamburger Menu




China approves Livzon Pharma's COVID-19 vaccine, among first new products in more than a year

China approves Livzon Pharma's COVID-19 vaccine, among first new products in more than a year

A medical worker collects a swab from a resident at a nucleic acid testing site following the COVID-19 outbreak in Shenzhen, Guangdong province, China on Aug 30, 2022. (Photo: Reuters/David Kirton)

BEIJING: China granted emergency use authorisation to Livzon Pharmaceutical Group's COVID-19 vaccine as a booster, the firm said on Friday (Sep 2), marking one of the two new products against the disease the country cleared in more than a year.

Livzon's vaccine, if rolled out to the public, would widen booster options for China's 1.4 billion population, of which 90 per cent have been vaccinated and nearly 60 per cent received a booster dose.

Most people in China have been injected with the inactivated vaccines from Sinovac or Sinopharm for primary vaccination, among seven domestically developed shots the country approved for use between 2020 and 2021.

Data showed that other vaccines, ranging from foreign mRNA products produced by Pfizer/BioNTech or Moderna to domestic non-inactivated candidates, elicited higher antibody readings against the Omicron variant as a mix-and-match booster compared with using a third Sinovac or Sinopharm dose.

Livzon's protein-based vaccine, adopting a different technology than Sinovac and Sinopharm's products, were among the two products Chinese officials said have recently been cleared for use. The other one has not been formally identified.

The regimen of one Livzon booster after two doses of inactivated vaccines had an efficacy of 61.35 per cent, Livzon said in February, citing preliminary data from a trial involving more than 10,000 participants and 110 cases, without providing details.

The combination had an efficacy of 60.81 per cent against Omicron, based on calculations involving 63 cases infected with the variant, a Livzon executive said on Friday, without specifying the severity of those cases, or which subvariants of Omicron the participants had contracted.

The company is working on bivalent or multivalent vaccine candidates, which include designs targeting the BA.5 subvariant of Omicron, after animal test data showed a candidate updated for BA.5 solely did not elicit broad neutralisation across variants, Yang Jiaming, deputy general manager at Livzon's vaccine unit, told an event.

China currently only allows one booster dose following primary vaccination. It has yet to approve any foreign-made doses.

BOOKMARK THIS: Our comprehensive coverage of the COVID-19 pandemic and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus pandemic:

Source: Reuters/ic


Also worth reading